At the World Nuclear Exhibition today, Westinghouse Electric Company and EDF signed a historic Memorandum of Understanding (MoU) to produce Cobalt-60 radioisotope in select Pressurized Water Reactors (PWR) owned and operated by EDF in France.
Cobalt-60 plays a critical role in the safety of medical devices and reduces pathogens in other products. Cobalt-60 also plays a vital role in the treatment of certain brain cancers. This MoU marks the first step for production in Europe of Cobalt-60 for medical uses.
Cédric Lewandowski, EDF Group Senior Executive Vice-President, Nuclear and Thermal, explained that: “Production of Cobalt-60 in EDF nuclear power plants shows that, in addition to its role of production of carbon-free electricity, nuclear energy can also help on global health, this is part of our contribution to the general interest.
by Hardware (PLCs, Remote Terminal Units, HMIs, Communication Systems), Software (On-premises, Cloud-based), Services (Professional, Managed), Sector Type (Solar, Wind, Hydropower) and Region
Download free sample pagesCobalt-60 is produced by exposing Cobalt-59, a stable isotope, with neutrons. In the MoU, Westinghouse would manufacture Cobalt-59 capsule fuel assembly inserts (COBAs) for EDF to manage in its PWRs to generate activated Cobalt-60. Westinghouse would drive the commercialization of the Cobalt-60.
Cédric Lewandowski, EDF Group Senior Executive Vice-President, Nuclear and Thermal (LEFT) and Patrick Fragman, Westinghouse President & CEO.
“We are delighted to partner with EDF in this key agreement that will expand and strengthen the global Cobalt-60 supply chain,” said Patrick Fragman, Westinghouse President & CEO. “We are fully committed to leverage nuclear energy to improve global health.”
EDF and Westinghouse will initiate a Feasibility Assessment and target an anticipated Cobalt-59 load date in the late 2020s with the first Cobalt-60 harvest in the early 2030s.
